# Presentation: 071062

## NFBIO:Update on NCI Imaging Activities

**Daniel C. Sullivan, M.D.**
**Cancer Imaging Program, DCTD, NCI**

## Basic/Translational Research

**In vivo Cellular and Molecular Imaging Centers (ICMIC)**
**Small Animal Imaging Resource Programs (SAIRP)**
**Network for Translational Research in Optical Imaging (NTROI)**
**Radionuclide Resource (Wash Univ)**

## Slide 3

## Technology Development

**PA’s for Technology Development, Bioengineering Research Grants (BRG), and Bioengineering Research Partnerships (BRP)**
**SBIR grants**

## Comments on Tech Development:

**SBIR program for small businesses**
**Large companies are somewhat at a disadvantage in competition with academician “grant-writers”; and Large companies may be at a disadvantage in Review (which is predominantly academicians)**
**Nevertheless, large companies do succeed in winning grants**

## NCI Assistance for Imaging Agent Development

**CIP uses contract vendors or sites to assist developers**
**Development of Contrast Imaging Drugs and Enhancers (DCIDE) – preclinical development**
**Phase 1 and 2 clinical trial contract sites (MGH, Univ Wash, JHU, VCU).**
**CIP:**
**“****Venture capitalists for the public good”**

## DCIDE; Phase 1,2 Trials

**CTA with AMI; IND’s for Combidex, ferrumoxytol; Trials active.**
**CTA with GE Healthcare; IND for FLT filed. Phase 1 trial in development.**
**3 “boxes” purchased and placed at contract sites for SOP’s of 3 other radiopharmaceuticals.**

## Clinical Trials

**R21 PA for “Quick Trials”**
**$250K/yr x 2 yrs**
**ACRIN (Cooperative Group for imaging trials)**
- _[www.acrin.org](http://www.acrin.org/)_
**CTEP Cooperative Groups**
**R01**

## Inter-agency activities

**Inter-agency Forum**
**Inter-agency Council**
**NCI-FDA Task Force**
**NCI-CMS Task Force**

## National Institute of Biomedical Imaging and Bioengineering (NIBIB)

**Emphasis on basic or generic technologies**
**Evaluation or validation of physical performance**
**Training grants**

## Imaging as a Biomarker

**Issues:**
**Reproducibility**
**Correlation with biological parameter**
**Reference standard**

## Imaging as a Biomarker

**Initial focus for NCI:**
**FDG-PET**
**DCE-MRI**
**Near-term focus**
**FLT-PET (IND done; Phase 1 in progress).**
**MRS**

## Current Activities

**Coordinated approach to FDG-PET correlative studies in NCI Cooperative Group therapy trials.**
**Infrastructure to facilitate central archiving and review of images from clinical trials**
**Collaboration with RSNA MIRC**

## Slide 14

## Relevant Workshops

**Imaging and Oncology: How to Build a Successful Partnership. October 14-15, 2004**
**MR in Clinical Assessment of Anti-Tumor Therapies.  November 21-22, 2004**
**The Role of FDG-PET in the Evaluation of Therapeutic Response in Cancer.  January 9-10, 2005**

## New Program: IRAT’s

**Imaging Response Assessment Teams**
**Cancer Center Supplements**
**(~$250 K/yr/site)**
**Imaging MD and PhD involvement into protocol development and data evaluation**
**Collaboration with the American Association of Cancer Institutes (AACI) and the American Cancer Society (ACS)**

## New RSNA Training Course

**Clinical Trial Methodology Course**
**January 7 – 13, 2006, Phoenix AZ**
**Competitive selection process**
**Each student will write a clinical trial protocol during the course.**
- _[www.rsna.org](http://www.rsna.org/)__ (Research programs)_

## Cancer Imaging Program

- _[imaging.cancer.gov](http://www.imaging.cancer.gov/)_
- _[cip.cancer.gov](http://www.cip.cancer.gov/)_
**301 496 9531**

## Tel: 301 496 9531

**CIP Vision Statement:**
**Cancer Imaging –**** **
**Visualize the problem**
**and direct the solution.**

**Tel: 301 496 9531**